Active Biotech Interim report January – September 2019


Third quarter in brief

  • A new business plan for laquinimod and tasquinimod, based on the extensive preclinical and clinical data previously generated, is in progress
  • Data on laquinimod from the Phase 2 LEGATO-HD study in Huntington’s disease was presented at the International congress of Parkinson’s disease and movement disorders

Events after the end of the period

  • The first patient in the Phase 1b trial of naptumomab estafenatox in combination with durvalumab in solid tumors has been dosed
  • Preclinical data on naptumomab estafenatox was presented at the Society for Immunotherapy of Cancer’s 34th Annual Meeting

Financial summary

MSEK Jul-Sep Jan-Sep Full-Year
  2019 2018 2019 2018 2018
Net sales 0,9 4,7 7,5 15,2 20,1
Operating loss -9,3 -6,9 -21,1 -22,8 -29,8
Loss after tax -9,3 -8,7 -22,9 -28,0 -36,9
Earnings per share (SEK) -0,06 -0,06 -0,16 -0,21 -0,27
Cash and cash equivalents (at close of period)     69,9 36,0 25,6

For further information, please contact:

  Helén Tuvesson, CEO
  Tel: +46 (0)46 19 21 56


  Hans Kolam, CFO
  Tel: +46 (0)46 19 20 44
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00

The report is also available at .

Active Biotech is obligated to make public the information contained in this report pursuant to the EU Market Abuse Regulation. This information was provided to the media, through the agency of the contact persons set out above, for publication on November 14, 2019 at 08.30 a.m. CET. 


About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Medtronic Named to FORTUNE’s 2020 World’s Most Admired Companies List21.1.2020 16:57:00 CETPress release

Global Leader in Medical Technology Ranks #2 in Industry on Annual List DUBLIN, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) has been named to FORTUNE’s 2020 World’s Most Admired Companies List. The global leader in medical technology landed at #2 in the Medical Products and Equipment industry. “We are honored to be selected by Fortune for this prestigious recognition,” said Omar Ishrak, Medtronic chairman and chief executive officer. “Our 90,000 people around the world strive every day to bring innovative products to market that achieve our longstanding Mission - to alleviate pain, restore health, and extend life. We seek to achieve this Mission responsibly, and we remain committed to being a company worthy of the trust and admiration of our investors, employees and customers.” The annual list measures corporate reputation among the world’s largest companies – the 1,000 largest U.S. companies by revenue, along with non-U.S. companies in Fortune’s Global 500 database that

The Private Placement of Secured Notes of AS PRFoods and the Results of the Placement21.1.2020 16:17:00 CETPress release

The Private Placement of Secured Notes of AS PRFoods and the Results of the Placement THIS NOTICE IS NOT INTENDED FOR PUBLICATION, ALLOCATION OR TRANSMISSION, IN PART OR WHOLLY, DIRECTLY OR INDIRECT, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR WHERE THE DISCLOSURE OR TRANSMISSION OF THIS INFORMATION IS NOT ALLOWED. By a company announcement dated 19 December 2020, AS PRFoods (hereinafter "PRFoods") informed investors that it was planning an issue of notes. PRFoods hereby notifies that the supervisory board of PRFoods has approved the principal terms and conditions of the note issue and has authorised the management board to issue up to 100,000 secured notes, with the maximum aggregate nominal value of up to EUR 10,000,000, nominal value of EUR 100 per note, interest rate of 6.25% per annum and maturity date on 22 January 2025 (hereinafter the “Notes”). Other than as brought out above, the material terms and conditions of the Notes

C-RAD Web Presentation Year-end Report 201921.1.2020 16:00:00 CETPress release

Presentation of the report for the fiscal year 2019: Date: Friday January 31, 2020 / kl. 11:00 CET Venue: Online Presentation Topic: C-RAD Year-end Report 2019 Procedure: Please register online through the website: After your registration, you will receive a confirmation via email. A recording of the presentation will be made accessible on the C-RAD website after the presentation. About C-RAD C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany and C-RAD (Shanghai) Medical Device Co Ltd in China. Cyrpa Inte

A subsidiary of PRFoods AS obtained an approval to expand fish farming in Sweden.21.1.2020 15:32:00 CETPress release

A subsidiary of PRFoods AS, Överumans Fisk AB obtained an approval to establish an additional fish farm in the Västerbotten region of Sweden. The permit is valid for fish farming and keeping fish over winter. The permit grants the right to use 2400 tonnes of fish feed to farm approx. 2200 tonnes of fish. The permit shall entry into force after the expiry of dispute time and shall be valid for 15 years. “An important part of PRFoods strategy is to expand the volume of fish farming in Finland, Sweden and Estonia. The permit in Sweden allows us to nearly triple the volume of farming in Sweden, and for this, our fish farming management team, led by Margus Rebane, has done outstanding work for many years. Fish from our own farms guarantees that our factories have high-quality and environmentally friendly raw material and we can provide fish products of excellent quality to consumers. The next step for the company is to establish a sustainable fish farming industry in Estonia, which would be

EDHEC-Scientific Beta Research Chair Publication Questions the Existence of a "Green" Factor21.1.2020 14:45:00 CETPress release

Press Release Boston, London, Nice, Paris, Singapore, Tokyo, January 21, 2020 EDHEC-Scientific Beta Research Chair Publication Questions the Existence of a "Green" Factor Study sees no evidence so far to support the existence of such a factor A new publication from the EDHEC-Scientific Beta "Advanced Factor & ESG Investing" research chair, entitled "The DeCarbonisation Factor: A New Academic Fiction?", by Abraham Lioui, Professor of Finance at EDHEC Business School and member of the EDHEC-Scientific Beta Research Chair, examines two recent papers, Cheema-Fox et al. (2019) and Bolton and Kacperczyk (2019), which looked at the financial market implications of firms’ carbon emissions. The Cheema-Fox et al. paper, entitled "Decarbonization Factors," has been widely marketed and often serves to support the usefulness of considering a green factor in the factor allocation menu. Faced with this assertion, Professor Lioui observed that the second paper contradicted the results of the first one

Boels Supplements the Tender Offer Document Relating to its Recommended Voluntary Public Cash Tender Offer for All Shares in Cramo Plc21.1.2020 14:00:00 CETPress release

Cramo Plc Stock Exchange Release 21 January, 2020 at 3.00 pm EET NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA OR HONG KONG, OR IN ANY OTHER JURISDICTION IN WHICH THE TENDER OFFER WOULD BE PROHIBITED BY APPLICABLE LAW. FOR FURTHER INFORMATION, SEE SECTION “IMPORTANT LEGAL INFORMATION” BELOW. Boels Supplements the Tender Offer Document Relating to its Recommended Voluntary Public Cash Tender Offer for All Shares in Cramo Plc Boels Topholding B.V. (“Boels” or the “Offeror”) has commenced a voluntary recommended public cash tender offer to purchase all of the issued and outstanding shares in Cramo Plc (“Cramo”) on November 25, 2019 (the “Tender Offer”). The acceptance period of the Tender Offer commenced on November 25, 2019 at 9:30 a.m. (Finnish time) and will expire on January 31, 2020 at 4:00 p.m. (Finnish time) (the “Offer Period”). The Finnish Financial Supervisory Authority has today appro